Pharmacological updates on Sotagliflozin in the treatment cardiac failure

Authors

  • Ms.Maralikar Mukta N. Doctor of Pharmacy, Research Scholar, Department of Pharmacology, Student of ASPM’s KT Patil College of Pharmacy, Siddharth Nagar, Barshi Road, Osmanabad-413 501, Maharashtra, India.
  • Ms.Chandel Pratiksha B. Doctor of Pharmacy, Research Scholar, Department of Pharmacology, Student of ASPM’s KT Patil College of Pharmacy, Siddharth Nagar, Barshi Road, Osmanabad-413 501, Maharashtra, India.
  • Mr.Gunjegaonkar Shivshankar M. M. Pharm, Ph.D., Associate Professor, Department of Pharmacology, Faculty of ASPM’s KT Patil College of Pharmacy, Siddharth Nagar, Barshi Road, Osmanabad-413 501, Maharashtra, India
  • Mr.Joshi Amol A. M. Pharm, Ph.D., Professor and Head of the Institute, ASPM’s KT Patil College of Pharmacy, Siddharth Nagar, Barshi Road, Osmanabad-413 501, Maharashtra, India.

Abstract

The heart and blood arteries make up the cardiovascular system. Any significant abnormal condition of the heart or blood vessels (arteries, veins) is referred to as Cardiovascular Disease (CVD)[1]. Coronary Heart Disease (CHD), stroke, peripheral vascular disease, congenital heart disease, endocarditis, and numerous more disorders are examples of cardiovascular diseases .Congestive heart failure(CHF), also referred to as Heart Failure (HF), condition, or a collection of signs and symptoms, brought on by a decline in the heart’s ability to pump blood. Leg swelling, extreme exhaustion, and shortness of breath are frequent symptoms. People who have shortness of breath throughout the night may wake up due to it happening during physical activity or when lying down[2].Heart failure does not typically result in chest pain including angina, but it could if the heart failure was brought on by a heart attack. The ejection fraction is the primary factor used to determine the degree of heart failure, however, symptoms are also taken into account[3][4].Obesity, kidney failure, liver diseases, anemia, and thyroid disease are additional illnesses that may present with symptoms comparable to heart failure.[5].The age-standardized rate (ASR) for prevalent instances of HF was 711.90 per 100,000 people (which is 7.06% lower than it was in 1990 (765.99 per 100,000 people there was 56.19 million (95%UI, 46.45-67.79) cases worldwide[6] Due to recent progress against communicable diseases, India’s population is aging, and by 2016 there will be 113 million more persons over 60 than there were in 1996 (62 million)[10] .since the lifetime risk of HF rises with age, the burden of HF is predicted to rise along with the aging population[7]. HF is mostly a disease of the elderly.The epidemiological transition,which was defined by Omron in 1971 and updated by Olshansky and Ault in 1986 and Yusuf and colleagues in 2005,[9] depicts changes in illness patterns as societies grow[8]. The etiology of heart failure may affect how it is treated. Drug and lifestyle modifications are frequently used as treatments.[11] Treating the underlying health issues could stop heart failure if it is the root cause.Heart failure may be treated using a cocktail of drugs. Depending on the etiology and symptoms of heart failure, different medications are utilized[12]. Heart failure medications include which consist of Angiotensin-converting enzyme (ACE) inhibitors:Eg., Enalapril, Lisinopril, Captopril,[13-15]etc.Beta-blockerseg. Metoprolol, Bisoprolol, Carvedilol, and Nebivolol[16-18].Positive inotropes eg. Digoxin, Dobutamine Alternative vasodilator: Isosorbide dinitrate, Hydralazine,[19-20] and Diuretics egFurosemide, Amiloride, Spironolactone.[21-23].

 

Published

2023-08-14

How to Cite

Ms.Maralikar Mukta N., Ms.Chandel Pratiksha B., Mr.Gunjegaonkar Shivshankar M., & Mr.Joshi Amol A. (2023). Pharmacological updates on Sotagliflozin in the treatment cardiac failure. Foundations and Trends in Modern Learning, (3). Retrieved from https://ojs.publisher.agency/index.php/FTML/article/view/1995

Issue

Section

Pharmaceutical Sciences